Idera Pharmaceuticals Acquires Aceragen
Acquisition includes late-stage rare disease portfolio with anticipated 2023 clinical milestones and first potential…
Read More...
Read More...
Browsing Tag
Idera Pharmaceuticals
Idera Pharmaceuticals Reports Second Quarter 2022 Financial Results
EXTON, Pa., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera,” the “Company,” “we,” “us,” or…
Read More...
Read More...
Idera Pharmaceuticals Announces Tilsotolimod Updates
EXTON, Pa., Dec. 14, 2021 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera,” the “Company,” “we,” “us,” and…
Read More...
Read More...
Idera Pharmaceuticals Announces Corporate Updates
EXTON, Pa., May 18, 2021 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera” or the “Company”) (Nasdaq: IDRA)…
Read More...
Read More...